CSF Biomarkers in Longitudinal Alzheimer Disease Cohorts: Pre-Analytic Challenges

被引:1
|
作者
Jonaitis, Erin M. [1 ,2 ,3 ]
Jeffers, Beckie [1 ,2 ,3 ]
VandenLangenberg, Monica [2 ,3 ]
Ma, Yue [2 ]
Van Hulle, Carol [2 ]
Langhough, Rebecca [2 ,3 ]
Du, Lianlian [2 ,4 ]
Chin, Nathaniel A. [3 ]
Przybelski, Robert J. [3 ]
Hogan, Kirk J. [5 ]
Christian, Bradley T. [2 ,6 ,7 ]
Betthauser, Tobey J. [2 ,3 ]
Okonkwo, Ozioma C. [2 ,3 ]
Bendlin, Barbara B. [2 ,3 ]
Asthana, Sanjay [2 ,8 ]
Carlsson, Cynthia M. [1 ,2 ,8 ]
Johnson, Sterling C. [1 ,2 ]
机构
[1] Univ Wisconsin, Wisconsin Alzheimers Inst, Sch Med & Publ Hlth, 600 Highland Ave CSC K6-440 MC4670, Madison, WI 53792 USA
[2] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr & Gerontol, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, Madison, WI 53792 USA
[6] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI 53792 USA
[7] Univ Wisconsin, Sch Med & Publ Hlth, Dept Psychiat, Madison, WI 53792 USA
[8] Wm S Middleton Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI USA
基金
美国国家卫生研究院;
关键词
D O I
10.1093/clinchem/hvad221
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background The sensitivity of amyloid to pre-analytic factors complicates cerebrospinal fluid (CSF) diagnostics for Alzheimer disease. We report reliability and validity evidence for automated immunoassays from frozen and fresh CSF samples in an ongoing, single-site research program.Methods CSF samples were obtained from 2 Wisconsin cohorts (1256 measurements; 727 participants). Levels of amyloid beta 1-42 (A beta 42), phosphorylated tau 181 (pTau181), and total tau (tTau) were obtained using an Elecsys cobas e 601 platform. Repeatability and fixed effects of storage tube type, extraction method, and freezing were assessed via mixed models. Concordance with amyloid positron emission tomography (PET) was investigated with 238 participants having a temporally proximal PET scan.Results Repeatability was high with intraclass correlation (ICC) >= 0.9, but tube type strongly affected measurements. Discriminative accuracy for PET amyloid positivity was strong across tube types (area under the curve [AUC]: A beta 42, 0.87; pTau181A beta 42 , 0.96), although optimal thresholds differed.Conclusions Under real-world conditions, the Elecsys platform had high repeatability. However, strong effects of pre-analytic factors suggest caution in drawing longitudinal inferences.
引用
收藏
页码:538 / 550
页数:13
相关论文
共 50 条
  • [31] Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers
    Martorana, Alessandro
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (04) : 407 - 413
  • [32] Are CSF Biomarkers Ready for Prime Time as Diagnostics for Alzheimer Disease?
    Voelker, Rebecca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (17): : 1887 - 1887
  • [33] Novel diagnostic biomarkers of Alzheimer's disease in human CSF
    Simonsen, AH
    Andreasen, N
    Waldemar, G
    Pirttilä, T
    Davies, HA
    Blennow, K
    NEUROBIOLOGY OF AGING, 2004, 25 : S366 - S366
  • [34] Association of PTHrP levels in CSF with Alzheimer's disease biomarkers
    Kushnir, Mark M.
    Michno, Wojciech
    Rockwood, Alan L.
    Blennow, Kaj
    Strathmann, Frederick G.
    Hanrieder, Jorg
    CLINICAL MASS SPECTROMETRY, 2019, 14 : 124 - 129
  • [35] CSF tau and Aβ42:: Logical biomarkers for Alzheimer's disease?
    Galasko, D
    NEUROBIOLOGY OF AGING, 1998, 19 (02) : 117 - 119
  • [36] TAU CONFORMATIONS: NOVEL CSF BIOMARKERS FOR ALZHEIMER'S DISEASE
    Driver, J.
    Chen, C.
    Kowall, N.
    Lu, K.
    GERONTOLOGIST, 2012, 52 : 135 - 136
  • [37] CSF Biomarkers for Alzheimer's Disease and Frontotemporal Lobar Degeneration
    Hu, William
    Chen-Plotkin, Alice
    Arnold, Steven
    Grossman, Murray
    Clark, Christopher
    Shaw, Les
    McCluskey, Leo
    El-Man, Lauren
    Karlawish, Jason
    Hurtig, Howard
    Siderowf, Andrew
    Soares, Holly
    Lee, Virginia
    Trojanowski, John
    NEUROLOGY, 2010, 74 (09) : A98 - A98
  • [38] Use of CSF biomarkers in Alzheimer’s disease clinical trials
    K. Blennow
    H. Zetterberg
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13
  • [39] Clinical indications for analysis of Alzheimer's disease CSF biomarkers
    Engelborghs, S.
    REVUE NEUROLOGIQUE, 2013, 169 (10) : 709 - 714
  • [40] CSF biomarkers predict a more malignant outcome in Alzheimer disease
    Wallin, A. K.
    Blennow, K.
    Zetterberg, H.
    Londos, E.
    Minthon, L.
    Hansson, O.
    NEUROLOGY, 2010, 74 (19) : 1531 - 1537